EPIRUS Biopharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EPIRUS Biopharmaceuticals, Inc. - overview
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Epirus is a US-based company that focuses on the development of biosimilar products.
Current Investors
Montreux Equity Partners, 5AM Ventures, TPG Biotech
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.epirusbiopharma.com
Company Stage
Merged
Total Amount Raised
Subscriber access only
EPIRUS Biopharmaceuticals, Inc. - financials
| Fiscal Year Ended | Dec 31, 2006 | Dec 31, 2007 | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 13,273,000 | 14,938,000 | 14,126,000 | 17,273,000 | 46,741,000 | 8,184,000 | 12,550,000 | - | - | - |
| % Revenue Growth (YoY) | - | 12.5% | (5.4%) | 22.3% | 170.6% | (82.5%) | 53.3% | - | - | - |
| EBITDA (USD) | (37,597,000) | (54,236,000) | (62,246,000) | (15,007,000) | 14,042,000 | (35,446,000) | (37,463,000) | - | - | - |
| Operating Income (USD) | (39,462,000) | (57,375,000) | (65,897,000) | (20,608,000) | (7,121,000) | (42,651,000) | (42,836,000) | - | - | - |
| Operating Margin | (297.3%) | (384.1%) | (466.5%) | (119.3%) | (15.2%) | (521.2%) | (341.3%) | - | - | - |
| % EBITDA Margin | (283.3%) | (363.1%) | (440.6%) | (86.9%) | 30.0% | (433.1%) | (298.5%) | - | - | - |
| NET Income (USD) | (34,288,000) | (53,343,000) | (65,133,000) | 15,388,000 | (35,045,000) | (42,043,000) | (44,327,000) | - | - | - |
| % Net Margin | (258.3%) | (357.1%) | (461.1%) | 89.1% | (75.0%) | (513.7%) | (353.2%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.